ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Return-on-Tangible-Equity : -63.10% (As of Dec. 2023)

ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Equity Chart

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Equity

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Equity falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Equity Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description